RxDoctor Payments Data

Richard Pannel, DO

Child & Adolescent Psychiatry · Oxford, MSNPI 1649473489

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $755, 9.0 times the $84 reported in 2019. Among child & adolescent psychiatry clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,370in general payments, 2019–2025

Across 101 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$567
  • Supernus Pharmaceuticals, Inc.$369
  • AbbVie$366
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$259
  • Otsuka America Pharmaceutical, Inc.$224
  • Sunovion Pharmaceuticals Inc.$167
  • plus $418 from 11 others

What the payments were for

  • Food & beverage$2,370100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,370 in reported general payments places this provider in the 90th percentile of 20 child & adolescent psychiatry providers in Mississippi.

See all child & adolescent psychiatry providers in Mississippi

Medicare billing

Part B allowed, 2024
$89,442
Medicare patients
44
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$98,181
IngrezzaValbenazine Tosylate12$93,565
Thioridazine Hcl127$6,997
Naltrexone Hcl38$4,494
Divalproex Sodium ErDivalproex Sodium107$4,348
Olanzapine312$4,148
Chlorpromazine Hcl31$3,427
Risperidone363$2,885
Divalproex Sodium130$2,840
Quetiapine Fumarate189$2,719
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl12$2,175
Levocarnitine13$2,088
Lamotrigine ErLamotrigine12$1,750
Haloperidol38$1,713
Clomipramine Hcl41$1,144

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →